10-Q: Foghorn Therapeutics Q2 2026: Collaboration Revenue Surges Amidst Ongoing Losses

Foghorn Therapeutics reports a substantial increase in collaboration revenue for Q2 2026, driven by a catch-up adjustment, while operating expenses decrease, though net losses persist.

Summary

• Foghorn Therapeutics reported increased collaboration revenue of $16.1 million for the three months ended June 30, 2026, up from $7.6 million in the prior year period, largely due to a $14.2 million cumulative catch-up adjustment related to the scheduled expiration of the research term in December 2026.
• Total operating expenses decreased to $24.9 million from $28.7 million in the prior year's comparable period, with research and development expenses falling to $18.5 million from $21.8 million.
• General and administrative expenses also saw a decrease, totaling $6.4 million compared to $6.9 million in the prior year.
• The company reported a net loss of $7.2 million for the quarter, an improvement from a $17.9 million loss in the same period last year.
• As of June 30, 2026, Foghorn Therapeutics had cash, cash equivalents, and marketable securities totaling $167.6 million, which is expected to fund operations for at least 12 months.
• The company continues to advance its pipeline, including the FHD-909 program in collaboration with Eli Lilly and Company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with significant collaboration revenue growth offset by continued operating losses and a need for future funding.

Positives

• Collaboration revenue significantly increased to $16.1 million for the three months ended June 30, 2026, from $7.6 million in the prior year, primarily due to a $14.2 million cumulative catch-up adjustment.
• Total operating expenses decreased by $3.8 million to $24.9 million for the quarter compared to the prior year.
• Research and development expenses decreased by $3.3 million to $18.5 million for the quarter.
• General and administrative expenses decreased by $0.5 million to $6.4 million for the quarter.
• Net loss improved to $7.2 million for the quarter, compared to a $17.9 million net loss in the prior year's comparable period.
• Cash, cash equivalents, and marketable securities stood at $167.6 million as of June 30, 2026, providing an estimated runway of at least 12 months.

Negatives

• The company continues to incur significant operating losses, with a net loss of $7.2 million for the quarter and an accumulated deficit of $659.5 million as of June 30, 2026.
• The company expects to continue generating operating losses and requires substantial additional funding.
• The $14.2 million catch-up adjustment in collaboration revenue is a one-time event related to the research term expiration, not indicative of ongoing operational revenue growth.
• The decrease in R&D expenses for Lilly partnered programs ($4.4 million) and FHD-286 ($0.6 million) is partly due to discontinuing certain development activities.
• Interest income decreased due to a lower average balance of marketable securities.

Risks

• The company is subject to risks similar to other clinical-stage biopharmaceutical companies, including dependence on key individuals, the need to develop commercially viable products, and competition.
• There is no assurance that research and development will be successfully completed, that intellectual property will be maintained, or that products will obtain regulatory approval or be commercially viable.
• The company expects to continue to generate operating losses and requires additional financing, which may not be available on acceptable terms or at all.
• Failure to obtain funding could force the company to delay, reduce, or eliminate research and development programs.
• The company's ability to generate revenue depends on the successful development and commercialization of its product candidates.
• The company is subject to general economic conditions, including recessionary conditions, interest rates, monetary fluctuations, and supply chain constraints.
• Ongoing and potential geopolitical instability and armed conflicts pose risks.
• The company is subject to statutory and regulatory developments, particularly in China, including its Anti-Foreign Sanctions Law.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for at least the next several years. It anticipates substantial increases in expenses related to advancing its pipeline, hiring personnel, expanding platform capabilities, and operating as a public company. Foghorn expects its cash, cash equivalents, and marketable securities to be sufficient to fund its operations for at least 12 months, but will require additional funding through equity offerings, debt financings, or collaborations.

Management Comments

• The company is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system.
• To our knowledge, we are the only company with the ability to study and target the chromatin regulatory system at scale, in context, and in an integrated way.
• We believe our current pipeline has the potential to help more than 500,000 patients.
• We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities.
• We will need substantial additional funding to support our continuing operations and pursue our growth strategy.

Industry Context

StockSavvy.ai notes that Foghorn Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on novel therapeutic approaches targeting the chromatin regulatory system. The company's reliance on collaborations, particularly with a major player like Eli Lilly, is a common strategy for clinical-stage biotechs to fund development and leverage expertise. The increasing focus on precision medicine and targeted therapies aligns with broader industry trends.

Comparison to Industry Standards

• The company's net loss of $7.2 million for the quarter and $27.1 million for the six months is consistent with the typical financial profile of clinical-stage biopharmaceutical companies that are pre-revenue from product sales.
• The significant collaboration revenue of $16.1 million for the quarter, boosted by a catch-up adjustment, highlights the importance of strategic partnerships in this industry, similar to how companies like Moderna and BioNTech leveraged partnerships for vaccine development.
• The cash runway of at least 12 months, with $167.6 million in cash and marketable securities, is a critical metric for biotechs. Companies in this stage often aim for 18-24 months, but 12 months is considered a minimum to continue operations and pursue funding.
• The company's R&D expenses of $18.5 million for the quarter, while decreasing year-over-year, reflect ongoing investment in pipeline development, a standard practice for companies seeking to bring new therapies to market.

Legal Proceedings

• The company is not currently a party to any material litigation or legal proceedings that are probable to have a material adverse effect on its business.
• The company is currently under IRS audit related to the tax year ended December 31, 2023.

Related Party Transactions

• Consulting agreement with a scientific founder, extended to January 1, 2027, with de minimis payments during the quarter and $0.1 million for the six months.
• Eli Lilly and Company is a significant shareholder and collaborator; payments of $1.0 million and $1.4 million were made to Lilly during the three months ended June 30, 2026 and 2025, respectively, and $2.0 million for the six months ended June 30, 2026 and 2025.
• Funds affiliated with Flagship Pioneering, BVF Partners LP, Deerfield Management Co. LP, and FMR LLC, all 5% or greater shareholders, participated in the January 2026 Offering, contributing a total of $45.0 million in gross proceeds.

Stakeholder Impact

• Shareholders may see dilution if future capital raises are conducted at unfavorable terms.
• Employees may be impacted by potential delays or reductions in R&D programs if funding is not secured.
• Collaborators like Eli Lilly are directly involved in co-development and co-commercialization, with shared risks and rewards.
• Creditors and suppliers will be impacted by the company's ongoing need for financing and its ability to meet financial obligations.

Next Steps

• Continue advancing FHD-909 and other product candidates partnered with Lilly through preclinical and clinical development.
• Identify and advance additional research programs and product candidates.
• Initiate preclinical testing for any new product candidates identified.
• Obtain, maintain, expand, enforce, defend, and protect intellectual property.
• Hire additional research and development personnel.
• Add operational, legal, compliance, financial, and management information systems and personnel.
• Expand the capabilities of the Gene Traffic Control platform.
• Seek marketing approvals for product candidates that successfully complete clinical trials.

Key Dates

Recommendation

The company shows progress in collaboration revenue and expense management, leading to a reduced net loss. However, the persistent operating losses, significant accumulated deficit, and explicit need for substantial future funding, despite a 12-month cash runway, warrant a cautious 'hold' stance. The positive developments are tempered by the inherent risks and capital requirements of clinical-stage biopharmaceutical development.

Keywords

biopharmaceutical, clinical-stage, chromatin regulatory system, Gene Traffic Control platform, oncology, drug development, Eli Lilly, FHD-909